Taysha Gene Therapies
TSHA
71 hedge funds and large institutions have $111M invested in Taysha Gene Therapies in 2022 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 27 increasing their positions, 15 reducing their positions, and 9 closing their positions.
80% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 15
67% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 9
9% more funds holding
Funds holding: 65 → 71 (+6)
3.87% less ownership
Funds ownership: 48.1% → 44.23% (-3.9%)
34% less call options, than puts
Call options by funds: $108K | Put options by funds: $163K
49% less capital invested
Capital invested by funds: $215M → $111M (-$105M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$1.87M |
| 2 |
JP Morgan Chase
New York
|
+$1.51M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$1.29M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$961K |
| 5 |
Two Sigma Investments
New York
|
+$842K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO)
Austin,
Texas
|
-$13.4M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.37M |
| 3 |
BlackRock
New York
|
-$6.27M |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$913K |
| 5 |
Millennium Management
New York
|
-$700K |
TSHA Hedge Fund Activity: Q1 2022 in Review
71 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Taysha Gene Therapies (TSHA) for Q1 2022, worth a combined $111M — down 49% from $215M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new TSHA positions and 9 closed out — a net gain of 6 holders — while 27 added to existing stakes and 15 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $1.87M. The largest seller was University of Texas/Texas AM Investment Management Co (UTIMCO), exiting entirely with an estimated $13.4M sold.
- 71 institutional investors held Taysha Gene Therapies (TSHA) as of Q1 2022, up from 65 in Q4 2021.
- Funds reported $111M of Taysha Gene Therapies stock for Q1 2022, down 49% quarter-over-quarter.
- 15 funds opened new Taysha Gene Therapies positions in Q1 2022 and 9 closed out, a net change of +6 holders.
- The largest Taysha Gene Therapies buyer in Q1 2022 was Renaissance Technologies, an estimated $1.87M added.
- The largest Taysha Gene Therapies seller in Q1 2022 was University of Texas/Texas AM Investment Management Co (UTIMCO), an estimated $13.4M sold.
Based on aggregated 13F filings for Q1 2022.